RBRaquel M. Bernardi

Raquel M. Bernardi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Raquel M. Bernardi has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Ana Maria Bergold

    Universidade Federal do Rio Grande do Sul

    2 shared publications
  • Felipe Bianchini D'AVila

    Postgraduate Program in Pharmaceutical Sciences, Federal University of Rio Grande do Sul, Av. Ipiranga 2752, 90610-000 Porto Alegre, RS, Brazil

    1 shared publication
  • Pedro E Fröehlich

    Federal University of Rio Grande do Sul, Faculty of Pharmacy, Postgraduate Program in Pharmaceutical Sciences, 90610-000 Porto Alegre-RS, Brazil

    1 shared publication
  • Pedro E. Fröehlich

    Postgraduate Program in Pharmaceutical Sciences, Faculty of Pharmacy, Federal University of Rio Grande do Sul, 90610-000 Porto Alegre, RS, Brazil

    1 shared publication
  • Vítor Todeschini

    Postgraduate Program in Pharmaceutical Sciences, Faculty of Pharmacy, Federal University of Rio Grande do Sul, 90610-000 Porto Alegre, RS, Brazil

    1 shared publication

Latest Publications

  • A comparative study on the analytical performance of a charged aerosol detector and an ultraviolet detector for the RP-LC analysis of dabigatran etexilate in capsules

    by Raquel M. Bernardi, Felipe B. D'AVila, Vítor Todeschini, Pedro E. Fröehlich, Ana M. Bergold

    The reversed-phase liquid chromatography (RP-LC) method was validated for the assessment of dabigatran etexilate (DAB) in capsules using an ultraviolet detector (UV) and a charged aerosol detector (CAD) connected in series. The RP-LC method was carried out on a GL Sciences Inc. Inertsil ODS-2 column (250 mm × 4.6 mm I.D.). The mobile phase consisted of acetonitrile and ammonium acetate buffer (pH 5.5; 10 mM) (65 : 35, v/v) (flow rate 1.0 mL min−1). CAD detection was performed using a nitrogen pressure of 35 psi and a range of 100 pA and the UV detection at 225 nm. The chromatographic separation was obtained with a retention time of 6.7 min. Validation parameters such as specificity, linearity, precision, accuracy and robustness were evaluated. The method was linear over the concentration range of 1–70 μg mL−1 in both detectors. The specificity and stability-indicating capability of the method were proven through the degradation studies, which also show that there was no interference from the excipients. The method was precise and accurate, with the Plackett–Burman experimental design used to evaluate robustness, delivering results within the acceptable range. The method was successfully applied for DAB analysis and the results of the CAD and UV detectors were compared, showing a non-significant difference (P > 0.05).


  • Development and Validation of a Stability-Indicating Liquid Chromatography Method for the Determination of Dabigatran Etexilate in Capsules

    by Raquel M Bernardi, Pedro E Fröehlich, Ana M Bergold

    An RP-LC method was developed and validated for the determination of dabigatran etexilate in a capsule formulation. The LC method was carried out on a Zorbax C18 column (250 × 4.6 mm id). The mobile phase consisted of acetonitrile and a solution of triethylamine 0.1%, pH 6.0 adjusted with phosphoric acid (65 + 35, v/v) at a flow rate of 1.0 mL/min. The diode array detector was set at 225 nm. The chromatographic separation was obtained with retention time of 6.31 min, and linearity was in the range of 10–70 μg/mL (R2 = 0.9991). The specificity and stability-indicating capability of the method was proven through degradation studies and showing that there was no interference from the excipients. The accuracy was 100.23%, with an RSD of 1.34%. The LOD and LOQ were 0.04 and 10 μg/mL, respectively. Moreover, method validation demonstrated acceptable results for robustness and a system suitability test. The proposed method was applied for the analysis of the capsules to ensure their therapeutic efficacy.